Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia
interventions are at high-risk of a second relapse. Previous studies from investigators
reported an association between a positive minimal residual disease (MRD)-test after
transplant and an increased risk of subsequent relapse. Also, patients developing chronic
graft-versus-host disease (GvHD) after receiving DLI (donor lymphocyte infusion)for leukemia
relapse after a first allotransplant have a lower likelihood of a second relapse compared
with similar patients not developing chronic GvHD. And, our previous study also reported
patients with chronic GvHD after DLI was associated with a greater frequency of a negative
MRD-test and lower likelihood of subsequent relapse compared with similar persons not
developing chronic GvHD. Based on these data the investigators designed a randomized control
study to determine whether giving additional consolidation chemotherapy and DLI might
decrease likelihood of second relapse in persons without chronic GvHD or with a positive
MRD-test after initial post-relapse therapy with induction chemotherapy and DLI.